• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 5:20:07 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $EDAP alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)

     

    EDAP TMS S.A.

    (Name of Issuer)

     

    American Depositary Shares and Ordinary Shares, nominal value €0.13 per share

    (Title of Class of Securities)

     

    268311107**

     

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      [  ] Rule 13d-1(b)
         
      [X] Rule 13d-1(c)
         
      [  ] Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    ** There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 268311107 has been assigned to the American Depositary Shares of the Company, which are quoted on the Nasdaq Global Market under the symbol “EDAP.” Each American Depositary Share represents 1 Ordinary Share.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

       
    CUSIP No. 26831110713G/APage 2 of 8 Pages

     

         NAMES OF REPORTING PERSONS
         Opaleye Management Inc.
       
    1

       I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

       20-5648796

       
         CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
         (a)   [  ]
    2    (b)   [  ]
         SEC USE ONLY
       
    3  
         CITIZENSHIP OR PLACE OF ORGANIZATION
       
    4    Massachusetts

    NUMBER OF SHARES
    BENEFICIALLY OWNED
    BY EACH REPORTING
    PERSON WITH:
         SOLE VOTING POWER
       
    5    0
         SHARED VOTING POWER
       
    6    657,500 Ordinary Shares, nominal value €0.13 per share (“Ordinary Shares”) (represented by 657,500 American Depositary Shares (“ADS”))
         SOLE DISPOSITIVE POWER
       
    7    0
         SHARED DISPOSITIVE POWER
       
    8    657,500 Ordinary Shares (represented by 657,500 ADS)

         AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
    9

       657,500 Ordinary Shares (represented by 657,500 ADS)

         CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
    10    [  ]
         PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
    11    2.26% *
         TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
    12    CO

     

    * Based upon 29,141,566 Ordinary Shares outstanding on December, 2019 as reported by the Issuer on its annual report on Form 20-F filed with the Securities and Exchange Commission on April 16, 2020. This calculation does not include the exercise or conversion of outstanding securities of the Issuer.

     

       
    CUSIP No. 26831110713G/APage 3 of 8 Pages

     

         NAMES OF REPORTING PERSONS
    1

       I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

       Opaleye, L.P.

         CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
         (a) [  ]
    2    (b) [  ]
         SEC USE ONLY
       
    3  
         CITIZENSHIP OR PLACE OF ORGANIZATION
       
    4    Delaware

    NUMBER OF SHARES
    BENEFICIALLY OWNED
    BY EACH REPORTING
    PERSON WITH:
         SOLE VOTING POWER
       
    5    0
         SHARED VOTING POWER
       
    6    657,500 Ordinary Shares (represented by 657,500 ADS)
         SOLE DISPOSITIVE POWER
       
    7    0
         SHARED DISPOSITIVE POWER
       
    8    657,500 Ordinary Shares (represented by 657,500 ADS)

         AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
    9    657,500 Ordinary Shares (represented by 657,500 ADS)
         CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
    10    [  ]
         PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
    11    2.26% *
         TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
    12    PN

     

    * Based upon 29,141,566 Ordinary Shares outstanding on December, 2019 as reported by the Issuer on its annual report on Form 20-F filed with the Securities and Exchange Commission on April 16, 2020. This calculation does not include the exercise or conversion of outstanding securities of the Issuer.

     

       
    CUSIP No. 26831110713G/APage 4 of 8 Pages

     

         NAMES OF REPORTING PERSONS
    1

       I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

       James Silverman

         CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
         (a)   [  ]
    2    (b)   [  ]
         SEC USE ONLY
       
    3  
         CITIZENSHIP OR PLACE OF ORGANIZATION
       
    4    United States

    NUMBER OF SHARES
    BENEFICIALLY OWNED
    BY EACH REPORTING
    PERSON WITH:
         SOLE VOTING POWER
       
    5    0
         SHARED VOTING POWER
       
    6    657,500 Ordinary Shares (represented by 657,500 ADS)
         SOLE DISPOSITIVE POWER
       
    7    0
         SHARED DISPOSITIVE POWER
       
    8    657,500 Ordinary Shares (represented by 657,500 ADS)

         AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
    9    657,500 Ordinary Shares (represented by 657,500 ADS)
         CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
    10    [  ]
         PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
    11    2.26% *
         TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
    12    IN

     

    * Based upon 29,141,566 Ordinary Shares outstanding on December, 2019 as reported by the Issuer on its annual report on Form 20-F filed with the Securities and Exchange Commission on April 16, 2020. This calculation does not include the exercise or conversion of outstanding securities of the Issuer.

     

       
    CUSIP No. 26831110713G/APage 5 of 8 Pages

     

    Item 1(a).   Name of Issuer:
         
        The name of the issuer is EDAP TMS S.A. (the “Company”).
         
    Item 1(b).   Address of Issuer’s Principal Executive Offices:
         
        The Company’s principal executive offices are located at Parc Activite La Poudrette Lamartine, 4/6 Rue du Dauphine, 69120 Vaulx-en-Velin, France.
         
    Item 2(a).   Name of Person Filing.
         
        This statement is filed by the entities and persons listed below, who are collectively referred to herein as “Reporting Persons” with respect to the Ordinary Shares of the Company:
         
        Opaleye Fund
         
        Opaleye, L.P. (the “Opaleye Fund”), a private fund formed in the state of Delaware.
         
        Investment Manager
         
       

    Opaleye Management Inc. (the “Investment Manager”), with respect to the Ordinary Shares held by the Opaleye Fund, a private fund to which the Investment Manager serves as investment manager. The Investment Manager also serves as a portfolio manager for a separate managed account (the “Managed Account”) and may be deemed to indirectly beneficially own securities owned by the Managed Account. The Investment Manager disclaims beneficial ownership of the shares held by the Managed Account.

         
        Reporting Individual
         
        Mr. James Silverman (the “Reporting Individual”), with respect to the Ordinary Shares held by the Opaleye Fund. Mr. Silverman is the President of the Investment Manager.
         
    Item 2(b).   Address of Principal Business Office or, if None, Residence.
         
        One Boston Place, 26th Floor
        Boston, Massachusetts 02108
         
    Item 2(c).   Citizenship.
         
        Citizenship is set forth in Row 4 of the cover page for each Reporting Person and is incorporated herein by reference for each such Reporting Person.
         
    Item 2(d).   Title of Class of Securities.
         
       

    Ordinary Shares, nominal value €0.13 per share (“Ordinary Shares”) represented by American Depositary Shares (“ADS”), each of which represents one Ordinary Share.

         
    Item 2(e).   CUSIP Number.
         
        There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 268311107 has been assigned to the ADS, which are quoted on the Nasdaq Global Market under the symbol “EDAP”.

     

       
    CUSIP No. 26831110713G/APage 6 of 8 Pages

     

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    (a) [  ] Broker or dealer registered under Section 15 of the Exchange Act.
         
    (b) [  ] Bank as defined in Section 3(a)(6) of the Exchange Act.

     

    (c) [  ] Insurance company as defined in Section 3(a)(19) of the Exchange Act.
         
    (d) [  ] Investment company registered under Section 8 of the Investment Company Act.
         
    (e) [  ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f) [  ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); 
         
    (g) [  ] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
         
    (h) [  ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
         
    (i) [  ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
         
    (j) [  ] A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
         
    (k) [  ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________

     

    Item 4. Ownership.

     

    (a) Amount beneficially owned:
       
     

    Opaleye Management Inc. — 657,500 Ordinary Shares (represented by 657,500 ADS)*

      Opaleye, L.P. — 657,500 Ordinary Shares (represented by 657,500 ADS)*
      James Silverman — 657,500 Ordinary Shares (represented by 657,500 ADS)*

     

    * Includes 57,500 Ordinary Shares (represented by 57,500 ADS) held by the Managed Account

     

    (b)Percent of class:
      
     Opaleye Management Inc. — 2.26%**
     

    Opaleye, L.P. — 2.26%**

     

    James Silverman — 2.26%**

     

    * Based upon 29,141,566 Ordinary Shares outstanding on December, 2019 as reported by the Issuer on its annual report on Form 20-F filed with the Securities and Exchange Commission on April 16, 2020. This calculation does not include the exercise or conversion of outstanding securities of the Issuer.

     

       
    CUSIP No. 26831110713G/APage 7 of 8 Pages

     

    (c)Number of shares as to which the person has:
        
     (i) Sole power to vote or to direct the vote:
        
       Opaleye Management Inc. — 0 Ordinary Shares
       Opaleye, L.P. — 0 Ordinary Shares
       James Silverman — 0 Ordinary Shares

     

     (ii) Shared power to vote or to direct the vote:
        
       Opaleye Management Inc. — 657,500 Ordinary Shares (represented by 657,500 ADS)*
       Opaleye, L.P. — 657,500 Ordinary Shares (represented by 657,500 ADS)*
       James Silverman — 657,500 Ordinary Shares (represented by 657,500 ADS)*

     

    * Includes 57,500 Ordinary Shares (represented by 57,500 ADS) held by the Managed Account

     

     (iii) Sole power to dispose or to direct the disposition of:
        
       Opaleye Management Inc. — 0 Ordinary Shares
       Opaleye, L.P. — 0 Ordinary Shares
       James Silverman — 0 Ordinary Shares

     

     (iv) Shared power to dispose or to direct the disposition of:
        
       Opaleye Management Inc. — 657,500 Ordinary Shares (represented by 657,500 ADS)*
       Opaleye, L.P. — 657,500 Ordinary Shares (represented by 657,500 ADS)*
       James Silverman — 657,500 Ordinary Shares (represented by 657,500 ADS)*

     

    * Includes 57,500 Ordinary Shares (represented by 57,500 ADS) held by the Managed Account

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

       
    CUSIP No. 26831110713G/APage 8 of 8 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 12, 2021 By: /s/ James Silverman
        James Silverman
         
      Opaleye, L.P.
         
    Date: February 12, 2021 By: /s/ James Silverman
      Name:  James Silverman
      Title: Managing Member of Opaleye GP LLC,
        the General Partner of Opaleye, L.P.
         
      Opaleye Management Inc.
         
    Date: February 12, 2021 By: /s/ James Silverman
      Name: James Silverman
      Title: President

     

     
     

     

    JOINT FILING AGREEMENT

     

    This Joint Filing Agreement, dated February 12, 2021, is entered into by and among Opaleye Management Inc., a Massachusetts corporation, Opaleye, L.P., a Delaware limited partnership and James Silverman, an individual (collectively referred to herein as (the “Filers”). Each of the Filers may be required to file with the U.S. Securities and Exchange Commission a statement on Schedule 13G with respect to the Ordinary Shares (represented by ADS, each of which represents one Ordinary Share) of the Issuer beneficially owned by them from time to time. Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule. This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.

     

    DATED: February 12, 2021

     

      By: /s/ James Silverman
        James Silverman
         
      Opaleye, L.P.  
         
      By: /s/ James Silverman
      Name:  James Silverman
      Title: Managing Member of Opaleye GP LLC,
        the General Partner of Opaleye, L.P.
         
      Opaleye Management Inc.  
         
      By: /s/ James Silverman
      Name: James Silverman
      Title: President

     

       

    Get the next $EDAP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EDAP

    DatePrice TargetRatingAnalyst
    4/4/2025$2.00Buy → Hold
    Jefferies
    11/1/2022$11.00Buy
    Jefferies
    11/19/2021$12.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EDAP
    Leadership Updates

    Live Leadership Updates

    See more
    • EDAP Appoints Joshua H. Levine to Board of Directors

      PDF Version AUSTIN, Texas, January 10, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced the appointment of Joshua H. Levine to its Board of Directors.  "We are pleased to welcome Josh Levine to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. "Josh brings a wealth of executive experience and a track record of growing shareholder value by focusing on transformative, high growth business strategies within the medical technology sector. As EDAP continues to grow the market for its leading Focal One   robotic HIFU platform, Josh will help shape our strategic vision and ex

      1/10/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP Appoints Fran Schulz to Board of Directors

      PDF Version LYON, France, July 8, 2024 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced the appointment of Fran Schulz to its Board of Directors. "We are pleased to welcome Fran Schulz to our Board of Directors," said Marc Oczachowski, Chairman of the Board of EDAP TMS. "Fran brings a wealth of executive experience in the healthcare industry, and her expertise spans across a broad array of strategic finance and accounting functions. She also possesses an in-depth understanding of U.S. and international regulatory issues, which will further strengthen our Board's leadership as we continue to expand Focal One global

      7/8/24 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP Appoints New Executive Leaders to Strengthen Europe and Middle East Commercial Operations

      New appointments bring significant commercial experience with a focus on growing key strategic markets Expands executive leadership in growing disruptive, robotics-based capital equipment in both Urology and Gynecology therapeutic applications LYON, France, June 3, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today announced the appointments of Damien Desmedt and Alexander Fromm to further strengthen the Company's European and Middle Eastern commercial leadership. Mr. Desmedt has been appointed Vice President of Sales for Europe, Middle East, Africa, and India (EMEAI), and Mr. Fromm has been appointed General Manager for Switzerland and will

      6/3/24 8:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $EDAP
    SEC Filings

    See more
    • SEC Form 20-F filed by EDAP TMS S.A.

      20-F - EDAP TMS SA (0001041934) (Filer)

      3/27/25 4:31:02 PM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 6-K filed by EDAP TMS S.A.

      6-K - EDAP TMS SA (0001041934) (Filer)

      3/27/25 7:41:18 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 6-K filed by EDAP TMS S.A.

      6-K - EDAP TMS SA (0001041934) (Filer)

      3/3/25 7:10:48 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $EDAP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025

      Company to host conference call and webcast on Thursday, May 15th at 8:30am EDT LYON, France, May 1, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2025, before the markets open on Thursday, May 15th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Date:                Thursd

      5/1/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP Announces Positive Results from the FARP Randomized Controlled Trial Presented at the American Urological Association (AUA) Annual Meeting

      Final 3-year outcome of Focal Ablation versus Radical Prostatectomy (FARP) Randomized Controlled Trial (RCT) presented at 120th AUA Annual Meeting on Sunday, April 27, 2025. Study achieved its primary endpoint and demonstrated that the rate of treatment failure in the Focal Ablation (FA) group is non-inferior to that in the Radical Prostatectomy (RP) group at the final 36-month follow-up. AUSTIN, Texas, April 29, 2025 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, announced the positive final results of the Focal Ablation Versus Radical Prostatectomy (FARP) Study, the first randomized controlled trial completed comparing ultrasound energy-based focal ablat

      4/29/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP To Launch New Focal One® i Robotic HIFU system at the Upcoming 120th American Urological Association (AUA) Annual Meeting

      Focal One i expands HIFUsion® patient-specific imaging compatibility to include PSMA PET, ExactVu™ Micro-Ultrasound, along with AI-driven and intelligent algorithms including Unfold AI™ and OnQ™ ProstateFocal One i extends HIFUsion capabilities to integrate Koelis® 3D biopsy maps and DynaCAD Urology datasetsFocal One i system will enable future capabilities including treatment streaming and recording, remote collaborative procedures and expanded clinical indications AUSTIN, Texas, April 24, 2025 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, announced the launch of the new Focal One i system at the upcoming 120th American Urological Association (AUA) Annua

      4/24/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $EDAP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EDAP TMS SA downgraded by Jefferies with a new price target

      Jefferies downgraded EDAP TMS SA from Buy to Hold and set a new price target of $2.00

      4/4/25 8:36:35 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Jefferies initiated coverage on EDAP TMS SA with a new price target

      Jefferies initiated coverage of EDAP TMS SA with a rating of Buy and set a new price target of $11.00

      11/1/22 6:28:24 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • HC Wainwright & Co. reiterated coverage on Edap TMS with a new price target

      HC Wainwright & Co. reiterated coverage of Edap TMS with a rating of Buy and set a new price target of $11.00 from $12.00 previously

      11/19/21 7:01:21 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $EDAP
    Financials

    Live finance-specific insights

    See more
    • EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025

      Company to host conference call and webcast on Thursday, May 15th at 8:30am EDT LYON, France, May 1, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2025, before the markets open on Thursday, May 15th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Date:                Thursd

      5/1/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP Reports Record HIFU Fourth Quarter and Full-Year 2024 Results

                  Record full-year 2024 HIFU revenue of USD 25.7 million, an increase of 15.3% over full-year 2023Record Q4 2024 HIFU revenue of USD 9.3 million, an increase of 15.0% over Q4 2023U.S. Focal One HIFU procedures grew 51% on a year-over-year basis in 2024Focal One receives CE Mark for the treatment of deep infiltrating endometriosisRecent landmark HIFI study publication demonstrates positive outcomes with Focal One® Robotic HIFU versus surgery in the management of prostate cancerFirst patients treated in Phase I/II study evaluating Focal One Robotic HIFU for the treatment of Benign Prostatic Hyperplasia (BPH)Company to host conference call and webcast today, March 27th, at 8:30 a.m.

      3/27/25 7:10:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP to Announce Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025

      Company to host conference call and webcast on Thursday, March 27th at 8:30am EDT AUSTIN, Texas, March 6, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024, before the markets open on Thursday, March 27th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Da

      3/6/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $EDAP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by EDAP TMS S.A.

      SC 13G/A - EDAP TMS SA (0001041934) (Subject)

      11/14/24 3:36:33 PM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by EDAP TMS S.A. (Amendment)

      SC 13G/A - EDAP TMS SA (0001041934) (Subject)

      2/2/24 9:41:45 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by EDAP TMS S.A. (Amendment)

      SC 13G/A - EDAP TMS SA (0001041934) (Subject)

      2/14/23 8:19:52 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care